pe26 schreef op 28 december 2015 21:08:
8 december 2015:And then, a lot of activities around our CF portfolio. With cystic fibrosis (CF) we are going for a triple combo therapy where we are combining a potentiator
with two different correctors, corrector 1 and corrector 2; different modes of action there. And that triple combination therapy should go into
patients in the first half 2017.
Very exciting program (CF); we are doing that in collaboration with AbbVie, the partner that we value for cystic fibrosis and where the relationship
actually is very good if there are any questions in that regard. We're all committed to move this forward and show that we've got the best combination
therapy for that patient population.